Literature DB >> 9189180

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.

E S Newlands1, M F Stevens, S R Wedge, R T Wheelhouse, C Brock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9189180     DOI： 10.1016/s0305-7372(97)90019-0

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  190 in total

1.  Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.

Authors:  Michael S Bobola; Douglas D Kolstoe; A Blank; John R Silber
Journal:  Mol Cancer Ther       Date:  2010-05       Impact factor: 6.261

Review 2.  Treatment considerations for MGMT-unmethylated glioblastoma.

Authors:  Jennie W Taylor; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

Review 3.  Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors.

Authors:  Hemant Sarin
Journal:  Ther Deliv       Date:  2010-08

4.  Temozolomide (Temodar).

Authors:  J R Wesolowski; P Rajdev; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-10       Impact factor: 3.825

5.  Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.

Authors:  Christina Kim; Christopher W Lee; Laurel Kovacic; Amil Shah; Richard Klasa; Kerry J Savage
Journal:  Oncologist       Date:  2010-06-10

6.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

7.  Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model.

Authors:  Byron C Masi; Betty M Tyler; Hansen Bow; Robert T Wicks; Yuan Xue; Henry Brem; Robert Langer; Michael J Cima
Journal:  Biomaterials       Date:  2012-05-14       Impact factor: 12.479

Review 8.  Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency.

Authors:  Julie K Horton; Samuel H Wilson
Journal:  DNA Repair (Amst)       Date:  2006-11-20

9.  EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest.

Authors:  Qi Yu; Libo Liu; Ping Wang; Yilong Yao; Yixue Xue; Yunhui Liu
Journal:  Cell Cycle       Date:  2017-04-24       Impact factor: 4.534

10.  Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system.

Authors:  Geoffrey A Geiger; Weili Fu; Gary D Kao
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.